MENU
LLY
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

LLY stock forecast, quote, news & analysis

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology... Show more

A.I.Advisor
published price charts
LLY
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for LLY with price predictions
Oct 06, 2026

LLY's Stochastic Oscillator is sitting in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LLY's RSI Oscillator exited the oversold zone, 17 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

Following a +1.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 263 of 376 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In 52 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.

The Moving Average Convergence Divergence Histogram (MACD) for LLY turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 33 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.

LLY moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for LLY crossed bearishly below the 50-day moving average on September 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.

The Aroon Indicator for LLY entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.

The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.153) is normal, around the industry mean (19.199). P/E Ratio (39.771) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). LLY has a moderately low Dividend Yield (0.006) as compared to the industry average of (0.025). LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).

The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Dividends

LLY paid dividends on September 10, 2026

Eli Lilly & Co LLY Stock Dividends
А dividend of $1.73 per share was paid with a record date of September 10, 2026, and an ex-dividend date of August 14, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 200.13B. The market cap for tickers in the group ranges from 4.8K to 1.06T. LLY holds the highest valuation in this group at 1.06T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 8%. NSRX experienced the highest price growth at 8%, while MIRA experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -11%. For the same stocks of the Industry, the average monthly volume growth was 15% and the average quarterly volume growth was -8%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 27
P/E Growth Rating: 53
Price Growth Rating: 56
SMR Rating: 59
Profit Risk Rating: 64
Seasonality Score: 2 (-100 ... +100)